◆ Market Data --:--
⛽ Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...

Eupraxia Pharmaceuticals Inc.

EPRX.TO TSX Healthcare Victoria, Canada
Loading stock data...
Stock Performance
Price History
- Drag to select time range -
Market Data
Market Cap 575.9M
P/E Ratio -
52-Week High -
52-Week Low -
Avg Volume -
Beta -
Forward P/E -
Dividend Yield -
EV/Revenue -
Price/Book -
Business Overview

Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.

Healthcare Biotechnology TSX
Key Financial Metrics
-
Revenue
-25.5M
Net Income
C$-0.76
EPS (Diluted)
-30.1M
Free Cash Flow
Profitability
Gross Margin -
Operating Margin -
Net Profit Margin -
EBITDA -25.0M
Returns & Efficiency
Return on Assets (ROA) -73.0%
Return on Equity (ROE) -76.3%
Dividend Yield -
Payout Ratio -
Financial Health
Total Assets 34.9M
Total Debt 71,859
Debt to Equity 0.00x
Current Ratio 11.10
Company Info
IndustryBiotechnology
HQVictoria, Canada
Employees33
Fiscal Year End1735603200
CurrencyCAD
Websitewww.eupraxiapharma.com
Peers
7.9B
P/E: --
2.5B
P/E: 12.0
2.5B
P/E: 23.7
2.2B
P/E: 53.2
1.4B
P/E: 24.1
1.2B
P/E: --
1.1B
P/E: --
631.8M
P/E: --
Insider Activity
Sentiment Bullish
Shares Bought 1,715,848
Shares Sold 0
Total Transactions 40
SEDAR+ Filings
View All Filings
1
Annual Reports
12
Quarterly Reports
12
MD&A
63
News Releases
7
Material Changes
5
Prospectuses
6
Governance
24
Certifications
31
Other

● Interim financial statements/report – English.pdf
2025-11-04
● Interim financial statements/report – English.pdf
2025-08-12
● Interim financial statements/report – English.pdf
2024-11-07
● Interim financial statements/report – English.pdf
2024-08-07
● Interim financial statements/report – English.pdf
2023-11-14
View all 12 quarterly reports →

● Interim MD&A - English.pdf
2025-11-04
● Interim MD&A - English.pdf
2025-08-12
● Interim MD&A - English.pdf
2024-11-07
● Interim MD&A - English.pdf
2024-08-07
● Interim MD&A - English.pdf
2023-11-14
View all 12 md&a →

● News release - English.pdf
2026-02-19
● News release - English.pdf
2026-02-18
● News release - English.pdf
2026-01-08
● News release - English.pdf
2025-11-13
● News release - English.pdf
2025-11-04
View all 63 news releases →

● Material change report - English.pdf
2025-09-25
● Material change report - English.pdf
2024-11-06
● Material change report - English.pdf
2024-10-03
● Material change report - English.pdf
2024-08-07
● Material change report - English.pdf
2023-09-08
View all 7 material changes →

● Prospectus (non pricing) supplement (other than ATM) – English.pdf
2026-02-19
● Draft shelf prospectus supplement – English.pdf
2026-02-18
● Prospectus (non pricing) supplement (other than ATM) – English.pdf
2025-09-23
● Draft shelf prospectus supplement – English.pdf
2025-09-22
● Preliminary short form prospectus – English.pdf
2021-12-13

● Form of proxy - English.pdf
2025-05-09
● Management information circular - English.pdf
2025-05-09
● Management information circular - English.pdf
2022-05-11
● Form of proxy - English.pdf
2022-05-11
● Form of proxy - English.pdf
2021-11-10
View all 6 governance →

● 52-109F2 - Certification of interim filings - CEO (E).pdf
2025-11-04
● 52-109F2 - Certification of interim filings - CFO (E).pdf
2025-11-04
● 52-109F2 - Certification of interim filings - CEO (E).pdf
2025-08-12
● 52-109F2 - Certification of interim filings - CFO (E).pdf
2025-08-12
● 52-109F2 - Certification of interim filings - CFO (E).pdf
2024-11-07
View all 24 certifications →

● Consent letter of issuer's legal counsel.pdf
2026-02-19
● Consent letter(s) of other legal counsel.pdf
2026-02-19
● Underwriting or agency agreements (or amendment thereto).pdf
2026-02-19
● Underwriting or agency agreements (or amendment thereto).pdf
2025-09-23
● Consent letter of underwriters' legal counsel.pdf
2025-09-23
View all 31 other →
Interactive Charts
Full Chart View
Company Profile
General Information
Company NameEupraxia Pharmaceuticals Inc.
TickerEPRX.TO
ExchangeTSX
SectorHealthcare
IndustryBiotechnology
HeadquartersVictoria, Canada
Employees33
Fiscal Year End1735603200
CurrencyCAD
Websitewww.eupraxiapharma.com
Financial Summary
Market Cap575.9M
RevenueN/A
Net Income-25.5M
P/E RatioN/A
EPS (Diluted)C$-0.76
Net MarginN/A
ROE-76.3%
Dividend YieldN/A
Business Description
Eupraxia Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of products to address therapeutic areas with unmet medical need. The company's proprietary Diffusphere technology optimizes drug delivery for applications with significant unmet medical need. Its lead product candidates include EP-104IAR, which is in Phase III clinical trial for the treatment of unmet medical needs and pain relief for knee osteoarthritis; EP-104GI that is in Phase II clinical trial for treating eosinophilic esophagitis; and EP-104, which is under preclinical studies for the treatment of other inflammatory joint conditions, benign structures of the esophagus, and epidural delivery. The company was formerly known as Plaza Capital Partners Inc. and changed its name to Eupraxia Pharmaceuticals Inc. in May 2012. Eupraxia Pharmaceuticals Inc. was incorporated in 2011 and is headquartered in Victoria, Canada.
NEWS
Loading news...
TRENDING
Loading...